The best Zepbound (tirzepatide) alternatives in 2026 are Wegovy (semaglutide) for similar high-efficacy weight loss and the new Wegovy pill for needle-free convenience. While Zepbound often shows superior results, alternatives offer better insurance coverage for specific conditions or lower-cost, daily options.
Zepbound alternatives include same-class GLP-1 medications like Wegovy (semaglutide), Mounjaro (tirzepatide), and Saxenda (liraglutide), along with non-GLP-1 prescriptions such as Contrave, Qsymia, and Plenity. Compounded tirzepatide and compounded semaglutide are additional options when a licensed provider determines medical necessity.
Plenty of patients land on Zepbound first and then run into a wall. Their plan won’t cover it, the cash price feels impossible, or a provider suggests a different medication might suit their history better. Knowing what alternatives exist, how they compare in clinical trials, and who pays for what makes the next step less of a guessing game.
At Harmonia Health Solutions, we connect patients with licensed medical providers who review the full picture and prescribe what fits. That includes branded GLP-1 medications, tirzepatide-based and semaglutide-based options when a provider determines medical necessity, and non-GLP-1 alternatives for patients who want a different route entirely.
Ready to find the right fit? Contact us today and get matched with a licensed provider.
Zepbound is the brand name for tirzepatide, which was FDA-approved in November 2023 for chronic weight management. It activates two appetite-regulating hormones (GIP and GLP-1) and produces some of the largest weight-loss figures in the field. That same headline result is why so many patients hit roadblocks getting it.
The most common reasons patients start looking elsewhere:
Insurance won’t cover it: Many commercial plans exclude GLP-1s when prescribed for obesity, and Medicare’s statutory exclusion on weight-loss drugs is still in place in 2026 outside narrow exceptions.Alternatives fall into three buckets: the same active ingredient as Zepbound, the same drug class, and a different mechanism entirely. The right fit usually depends on health history, insurance status, and how a patient responds to early doses.
Mounjaro contains the same active ingredient as Zepbound, tirzepatide, but is FDA-approved for type 2 diabetes rather than for chronic weight management. Some providers prescribe it off-label when clinically appropriate.
Compounded tirzepatide is another route: a licensed medical provider may prescribe it when they determine compounded therapy is medically necessary for a specific patient. This is the framework we use for our compounded tirzepatide program.
Wegovy, Ozempic, and Rybelsus all use semaglutide as the active ingredient. Wegovy is FDA-approved for chronic weight management. Ozempic is approved for type 2 diabetes and commonly prescribed off-label for weight.
Rybelsus is the oral tablet form, approved for diabetes. Patients who want a same-class alternative to Zepbound’s tirzepatide often start with semaglutide, and we run a semaglutide program for eligible patients.
Daily injection is the other GLP-1 route. Saxenda (FDA-approved for weight management) and Victoza (FDA-approved for diabetes) both use liraglutide and require a once-a-day shot rather than once a week. Average weight loss is lower with tirzepatide or semaglutide in clinical trials, so these aren’t typically a first choice for patients prioritizing the largest average reductions seen in trials.
For patients who can’t or don’t want to take a GLP-1, several non-GLP-1 prescriptions are FDA-approved for chronic weight management. Contrave combines naltrexone and bupropion; we offer Contrave for weight management. Qsymia combines phentermine and topiramate. Plenity is an FDA-cleared oral hydrogel device that expands in the stomach to support fullness alongside diet and exercise.
Metformin sits at a different price point and pace. It isn’t FDA-approved for weight loss, but providers commonly prescribe it off-label, especially for patients with insulin resistance or PCOS. Effects are modest compared with GLP-1s, and the medication is well-studied and inexpensive.
Insurance coverage is the single biggest gatekeeper between patients and GLP-1 medications. For Zepbound and Wegovy, both FDA-approved for obesity, many commercial plans either exclude obesity drugs outright or require step therapy. For Ozempic and Mounjaro, coverage is more common when prescribed for diabetes but not for off-label weight use.
Medicare’s statutory exclusion on weight-loss drugs is still in effect in 2026. Per CMS demonstration authority, a short-term Medicare GLP-1 bridge program begins in July 2026 and runs through 2027, covering select medications under narrow eligibility, but the broader exclusion remains.
For patients without coverage, the cash-pay route is often the most predictable path. Our compounded semaglutide and compounded tirzepatide programs are subscription-based and do not require insurance approval; current pricing is published on each program page. HSA and FSA accounts may apply to prescription weight-loss costs, depending on the account’s rules. Patients should confirm with their plan administrator.
Trial averages don’t predict any one person’s result, but they show the broad range. Doses, trial length, and patient populations vary, so the percentages below are headline figures from the most-cited Phase 3 trials for each medication.
| Medication | Drug Class | Average Body Weight Loss in Trials | FDA Status for Weight Management |
|---|---|---|---|
| Zepbound (tirzepatide) | Dual GIP/GLP-1 agonist | Up to 22.5% at 72 weeks (SURMOUNT-1, 15mg) | FDA-approved November 2023 |
| Wegovy (semaglutide) | GLP-1 agonist | 14.9% at 68 weeks (STEP-1, 2.4mg) | FDA-approved June 2021 |
| Saxenda (liraglutide) | GLP-1 agonist (daily injection) | ~8% at 56 weeks (SCALE Obesity, 3mg) | FDA-approved December 2014 |
| Qsymia (phentermine + topiramate) | Non-GLP-1 combination | Up to ~10.9% at top dose (EQUIP) | FDA-approved July 2012 |
| Contrave (naltrexone + bupropion) | Non-GLP-1 combination | ~5% placebo-adjusted at 56 weeks (COR trials) | FDA-approved September 2014 |
| Phentermine alone | Sympathomimetic | ~5–7% short-term | FDA-approved for short-term use |
| Plenity (cellulose/citric acid hydrogel) | Oral medical device | Modest, in addition to diet/exercise | FDA-cleared April 2019 |
| Metformin (off-label) | Biguanide | ~1–3% short-term | Not FDA-approved for weight loss |
Trial figures were sourced from SURMOUNT-1 (NEJM, 2022), STEP-1 (NEJM, 2021), SCALE Obesity (NEJM, 2015), EQUIP (Obesity, 2012), and the COR-I/COR-II trials. Compounded tirzepatide and compounded semaglutide use the same active ingredients as their branded counterparts, but no clinical trials exist specifically on the compounded formulations.
A licensed provider considers the patient’s history, dose, and response over time rather than relying on a single trial figure.
The right Zepbound alternative depends on what’s available to you, what you can afford, and what your medical history supports. For some patients, that’s branded Wegovy or Mounjaro through insurance. For others, it’s a compounded GLP-1 prescribed under medical necessity. For a smaller group, a non-GLP-1 like Contrave is a better fit.
At Harmonia Health Solutions, our licensed medical providers review your full picture, recommend the option that fits, and stay involved as you progress. The first consultation is free, every prescription is reviewed by a licensed provider, and patients can switch programs if their first option isn’t working.
Call (225) 251-9225 to book your free consultation and start with a licensed provider today.
Medical Disclaimer: For informational purposes only. This article does not constitute medical advice. Compounded medications are prescribed only when a licensed medical provider determines they are medically necessary. Individual results vary. Consult a licensed provider before starting any new medication or weight-loss program.
No. Compounded tirzepatide uses the same active ingredient as Zepbound, but it is not FDA-approved. A licensed medical provider prescribes it only when they determine compounded therapy is medically necessary for a specific patient.
Sometimes. Many commercial plans exclude GLP-1s when prescribed for obesity, while others cover it with prior authorization. Medicare’s statutory exclusion on weight-loss drugs is still in place in 2026, with narrow exceptions for qualifying diagnoses.
Wegovy (semaglutide 2.4mg) is the next FDA-approved injectable for chronic weight management. Patients seeking the same active ingredient may discuss compounded tirzepatide with a licensed provider under the medical necessity framework.
Off-label, yes. Mounjaro contains tirzepatide and is FDA-approved for type 2 diabetes, but some providers prescribe it off-label for weight when clinically appropriate. Eligibility depends on health history and a provider’s review.
Oral options include Rybelsus (oral semaglutide, approved for diabetes), Contrave (oral combination), and Qsymia. We offer Rybelsus and Contrave through our program.
Cash pricing varies widely by medication and brand. Compounded GLP-1s through subscription telehealth are often the most affordable cash-pay route; current pricing is published on each weight-loss service page.
Compounded medications are prescribed only when a licensed medical provider determines they are medically necessary. They are not FDA-approved, and individual results vary. Patients should discuss risks and benefits with their provider before starting.
A free consultation begins the process. Eligibility is determined by a licensed medical provider after a health review, and shipping follows once a prescription is approved.
At Harmonia Health Solutions, your privacy and safety are our top priorities. We comply with HIPAA regulations to ensure that your personal information is protected, and our consultations are conducted by licensed healthcare professionals who adhere to the highest medical standards.
You’ll find information about longevity products and alternative health services, as well as news regarding the most recent holistic health and wellness research.
